Muzafaru Twinomujuni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muzafaru Twinomujuni has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Benson Musinguzi
Department of Medical Laboratory Sciences, Faculty of Health Sciences, Muni University, Arua, Uganda
11 shared publications - Henry Zamarano
Uganda Protestant Medical Bureau, Zion Estate, Bulaga, Kampala
10 shared publications - Taseera Kabanda
Department of Microbiology and Parasitology, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara City, Uganda
6 shared publications - Vicent Mwesigye
Mbarara University of Science and Technology
6 shared publications - Barbra Tuhamize
Department of Microbiology and Parasitology, Faculty of Health Sciences, Mbarara University of Science and Technology
5 shared publications - Charles Nkubi Bagenda
Department of Medical Laboratory Science, Mbarara University of Science and Technology, Mbarara City, Uganda
5 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Elsevier in SSRN Electronic Journal
Distribution and Antibiotic Susceptibility Profile of Bacterial Uropathogens Isolated from Pregnant Women Attending Antenatal Care at Itojo Hospital, Southwestern Uganda
Background: Urinary tract infections (UTIs) are among the most common bacterial infections during pregnancy and remain a significant cause of maternal and neonatal morbidity, particularly in low-resource settings. The increasing antimicrobial resistance among uropathogens has complicated the empirical management of UTIs, highlighting the need for local surveillance of bacterial distribution and antimicrobial susceptibility patterns.Objective: To determine the prevalence, distribution, and antimicrobial susceptibility profiles of bacterial uropathogens isolated from urine specimens of pregnant women attending antenatal Care at Itojo Hospital, Southwestern UgandaMethods: A cross-sectional study was conducted among 299 pregnant women attending the antenatal clinic. Midstream urine specimens were collected and cultured on Cystine Lactose Electrolyte Deficient (CLED) agar. Bacterial isolates were identified using conventional biochemical methods. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) 2024 guidelines.Results: Of the 299 urine specimens analysed, 89 (29.8%) yielded significant bacterial growth. Nine bacterial species were identified, with Escherichia coli (31.5%) and Klebsiella species (28.1%) being the predominant isolates. Other organisms included Citrobacter freundii, Enterobacter species, Proteus species, Morganella species, and Citrobacter divergens. Antimicrobial susceptibility testing revealed high resistance to cefotaxime and ceftriaxone, whereas imipenem demonstrated the highest antimicrobial activity against the isolated uropathogens.Conclusion: Bacterial uropathogens are common among pregnant women attending antenatal care in Ntungamo District. The high levels of resistance to commonly prescribed antibiotics underscore the need for routine urine culture and antimicrobial susceptibility testing, strengthened antimicrobial stewardship programmes, and evidence-based empirical treatment guidelines to improve the management of UTIs during pregnancy.
- 21 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDistribution and Antibiotic Susceptibility Profile of Bacterial Uropathogens Isolated from Pregnant Women Attending Antenatal Care at Itojo Hospital, Southwestern Uganda
Background: Urinary tract infections (UTIs) are among the most common bacterial infections during pregnancy and remain a significant cause of maternal and neonatal morbidity, particularly in low-resource settings. The increasing antimicrobial resistance among uropathogens has complicated the empirical management of UTIs, highlighting the need for local surveillance of bacterial distribution and antimicrobial susceptibility patterns.Objective: To determine the prevalence, distribution, and antimicrobial susceptibility profiles of bacterial uropathogens isolated from urine specimens of pregnant women attending antenatal Care at Itojo Hospital, Southwestern UgandaMethods: A cross-sectional study was conducted among 299 pregnant women attending the antenatal clinic. Midstream urine specimens were collected and cultured on Cystine Lactose Electrolyte Deficient (CLED) agar. Bacterial isolates were identified using conventional biochemical methods. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) 2024 guidelines.Results: Of the 299 urine specimens analysed, 89 (29.8%) yielded significant bacterial growth. Nine bacterial species were identified, with Escherichia coli (31.5%) and Klebsiella species (28.1%) being the predominant isolates. Other organisms included Citrobacter freundii, Enterobacter species, Proteus species, Morganella species, and Citrobacter divergens. Antimicrobial susceptibility testing revealed high resistance to cefotaxime and ceftriaxone, whereas imipenem demonstrated the highest antimicrobial activity against the isolated uropathogens.Conclusion: Bacterial uropathogens are common among pregnant women attending antenatal care in Ntungamo District. The high levels of resistance to commonly prescribed antibiotics underscore the need for routine urine culture and antimicrobial susceptibility testing, strengthened antimicrobial stewardship programmes, and evidence-based empirical treatment guidelines to improve the management of UTIs during pregnancy.
- Open Access
- 1 June 2026
- Published by Microbiology Society in Access Microbiology
- Vol. 8 (6)
Burden of extended-spectrum beta-lactamase-producing Enterobacteriaceae among cancer patients in Africa: a systematic review and meta-analysis
Background. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-P E ) exacerbate infections in cancer patients in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-P E among cancer patients in Africa from 1 January 2010 to 31 December 2024. Methods. We searched PubMed, Embase, Web of Science, CINAHL and Global Health for observational studies reporting ESBL-P E prevalence in cancer patients. Studies published in English from 1 January 2010 to 31 December 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms and assessed the quality of articles using the Newcastle–Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed with the I ² statistic and publication bias assessed with funnel plots and Egger’s test. Results. Twelve studies from 9 African countries, involving a total of 1,252 cancer patients and 643 identified events, were included. The pooled prevalence of ESBL-P E was 49.4% (95% CI: 36.0–62.9%, I ²=88.3%, P Escherichia coli and Klebsiella pneumoniae predominated. There was no evidence of publication bias based on funnel plot symmetry, Egger’s test ( t =−0.35, P =0.73) and trim-and-fill analysis (no studies imputed; adjusted estimate unchanged). Heterogeneity was substantial ( I ²=88.3%) with a wide 95% prediction interval (22.7–76.5%). Leave-one-out sensitivity analysis confirmed estimate stability (~49%) with persistently high heterogeneity ( I ² range: 81.4–89.4%). Conclusions. The high ESBL-P E prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship and intentional infection control measures.
- 1 June 2026
- Published by Microbiology Society in Access Microbiology
- Vol. 8 (6)
Open AccessBurden of extended-spectrum beta-lactamase-producing Enterobacteriaceae among cancer patients in Africa: a systematic review and meta-analysis
Background. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-P E ) exacerbate infections in cancer patients in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-P E among cancer patients in Africa from 1 January 2010 to 31 December 2024. Methods. We searched PubMed, Embase, Web of Science, CINAHL and Global Health for observational studies reporting ESBL-P E prevalence in cancer patients. Studies published in English from 1 January 2010 to 31 December 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms and assessed the quality of articles using the Newcastle–Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed with the I ² statistic and publication bias assessed with funnel plots and Egger’s test. Results. Twelve studies from 9 African countries, involving a total of 1,252 cancer patients and 643 identified events, were included. The pooled prevalence of ESBL-P E was 49.4% (95% CI: 36.0–62.9%, I ²=88.3%, P Escherichia coli and Klebsiella pneumoniae predominated. There was no evidence of publication bias based on funnel plot symmetry, Egger’s test ( t =−0.35, P =0.73) and trim-and-fill analysis (no studies imputed; adjusted estimate unchanged). Heterogeneity was substantial ( I ²=88.3%) with a wide 95% prediction interval (22.7–76.5%). Leave-one-out sensitivity analysis confirmed estimate stability (~49%) with persistently high heterogeneity ( I ² range: 81.4–89.4%). Conclusions. The high ESBL-P E prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship and intentional infection control measures.
- Open Access
- 1 March 2026
- Published by Microbiology Society in Access Microbiology
- Vol. 8 (3) , 001045.v5
Molecular characterization of extended-spectrum beta-lactamase-producing bacteria isolated from pregnant women’s urine at Itojo Hospital, South Western Uganda
Background. Extended-spectrum β -lactamase (ESBL)-producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents, complicating available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary to inform effective treatment guidelines. Objective. We sought to characterize ESBL-producing bacteria isolated from pregnant women’s urine at Itojo Hospital, Ntungamo district, Southwestern Uganda. Methods. We conducted a cross-sectional study where we collected and analysed 340 urine samples from 340 pregnant women. We did antimicrobial susceptibility testing using the Kirby–Bauer disc diffusion method. Isolates were screened for ESBL production and confirmed using the combination disc test. Genotypic characterization was confirmed using multiplex PCR to detect bla TEM, bla CTX-M and bla SHV genes. Results. The prevalence of ESBL-producing bacteria was 29.7% (101/340). Escherichia coli 36/101 (35.6%) and Klebsiella species 33/101 (32.7%) were predominant ESBL producers. Genotypic analysis revealed bla TEM 50/101 (49.5%) and bla CTX-M 31/101 (30.7%) as the most prevalent genes, while bla SHV was less common, 8/101 (7.9%) Conclusion. The high prevalence of ESBL-producing bacteria and their resistance to commonly used antibiotics highlighted the need for targeted antibiotic therapy, antimicrobial stewardship and regular molecular surveillance.
- 1 March 2026
- Published by Microbiology Society in Access Microbiology
- Vol. 8 (3) , 001045.v5
Open AccessMolecular characterization of extended-spectrum beta-lactamase-producing bacteria isolated from pregnant women’s urine at Itojo Hospital, South Western Uganda
Background. Extended-spectrum β -lactamase (ESBL)-producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents, complicating available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary to inform effective treatment guidelines. Objective. We sought to characterize ESBL-producing bacteria isolated from pregnant women’s urine at Itojo Hospital, Ntungamo district, Southwestern Uganda. Methods. We conducted a cross-sectional study where we collected and analysed 340 urine samples from 340 pregnant women. We did antimicrobial susceptibility testing using the Kirby–Bauer disc diffusion method. Isolates were screened for ESBL production and confirmed using the combination disc test. Genotypic characterization was confirmed using multiplex PCR to detect bla TEM, bla CTX-M and bla SHV genes. Results. The prevalence of ESBL-producing bacteria was 29.7% (101/340). Escherichia coli 36/101 (35.6%) and Klebsiella species 33/101 (32.7%) were predominant ESBL producers. Genotypic analysis revealed bla TEM 50/101 (49.5%) and bla CTX-M 31/101 (30.7%) as the most prevalent genes, while bla SHV was less common, 8/101 (7.9%) Conclusion. The high prevalence of ESBL-producing bacteria and their resistance to commonly used antibiotics highlighted the need for targeted antibiotic therapy, antimicrobial stewardship and regular molecular surveillance.
- Open Access
- 23 February 2026
- Published by Microbiology Society
- p. 001120.v3
Burden of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae among Cancer Patients in Africa: A Systematic Review and Meta-Analysis
Background : Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) exacerbate infections in cancer patients, in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-PE among cancer patients in Africa from 2010 to 2024. Methods: We searched PubMed, Embase, Web of Science, CINAHL, and Global Health for observational studies reporting ESBL-PE prevalence in cancer patients. Studies published in English from 2010 to 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed by I² statistics and publication bias by funnel plots and Egger’s test. Results: Twelve studies from nine African countries, involving 565 patients (305 events) and 687 samples (338 events), were included. The pooled prevalence was 49.9% (95% CI: 23.1%-76.9%, I² = 91.8%, p < 0.001) at the patient level and 48.1% (95% CI: 31.7%-65.0%, I² = 84.0%, p < 0.001) at the sample level. Escherichia coli and Klebsiella pneumoniae predominated, with high resistance to cephalosporins (median: 89.5%-90%) and fluoroquinolones but preserved carbapenem efficacy. Publication bias was evident, and heterogeneity persisted after sensitivity analysis. Conclusions: The high ESBL-PE prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship, and intentional infection control measures.
- 23 February 2026
- Published by Microbiology Society
- p. 001120.v3
Open AccessBurden of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae among Cancer Patients in Africa: A Systematic Review and Meta-Analysis
Background : Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) exacerbate infections in cancer patients, in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-PE among cancer patients in Africa from 2010 to 2024. Methods: We searched PubMed, Embase, Web of Science, CINAHL, and Global Health for observational studies reporting ESBL-PE prevalence in cancer patients. Studies published in English from 2010 to 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed by I² statistics and publication bias by funnel plots and Egger’s test. Results: Twelve studies from nine African countries, involving 565 patients (305 events) and 687 samples (338 events), were included. The pooled prevalence was 49.9% (95% CI: 23.1%-76.9%, I² = 91.8%, p < 0.001) at the patient level and 48.1% (95% CI: 31.7%-65.0%, I² = 84.0%, p < 0.001) at the sample level. Escherichia coli and Klebsiella pneumoniae predominated, with high resistance to cephalosporins (median: 89.5%-90%) and fluoroquinolones but preserved carbapenem efficacy. Publication bias was evident, and heterogeneity persisted after sensitivity analysis. Conclusions: The high ESBL-PE prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship, and intentional infection control measures.
- Open Access
- 18 February 2026
- Published by Microbiology Society
- p. 001045.v4
Prevalence and Molecular Characterization of Extended Spectrum Beta Lactamase Bacteria Causing Urinary Tract Infections in Pregnant Mothers at Itojo Hospital, South Western Uganda
Background Extended-spectrum β-lactamase (ESBL) producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents that complicate available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary internationally to inform the effective treatment guidelines. Objective To determine the prevalence and molecular characterization of ESBL bacteria causing Urinary Tract Infections (UTIs) in women who are pregnant at the Itojo Hospital, Ntungamo District. Methods We conducted cross-sectional study where we collected and analyzed 340 urine samples. We did antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Isolates were screened for ESBL production and confirmed using the combination disk test (CDT). Genotypic characterization was confirmed using multiplex PCR to detect blaTEM, blaCTX-M and blaSHV genes. Results The prevalence of ESBL – producing bacteria was 29.7% (101/340). Escherichia coli (35.6%) and Klebsiella species (32.7%) were predominant ESBL producers. Genotypic analysis revealed blaTEM (49.5%) and blaCTX-M (30.7%) as the most prevalent genes, while blaSHV was less common (7.9%) Conclusion The high prevalence of ESBL–producing bacteria and their resistance to commonly used antibiotics highlight the need for targeted antibiotic therapy, antimicrobial stewardship, and regular molecular surveillance.
- 18 February 2026
- Published by Microbiology Society
- p. 001045.v4
Open AccessPrevalence and Molecular Characterization of Extended Spectrum Beta Lactamase Bacteria Causing Urinary Tract Infections in Pregnant Mothers at Itojo Hospital, South Western Uganda
Background Extended-spectrum β-lactamase (ESBL) producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents that complicate available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary internationally to inform the effective treatment guidelines. Objective To determine the prevalence and molecular characterization of ESBL bacteria causing Urinary Tract Infections (UTIs) in women who are pregnant at the Itojo Hospital, Ntungamo District. Methods We conducted cross-sectional study where we collected and analyzed 340 urine samples. We did antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Isolates were screened for ESBL production and confirmed using the combination disk test (CDT). Genotypic characterization was confirmed using multiplex PCR to detect blaTEM, blaCTX-M and blaSHV genes. Results The prevalence of ESBL – producing bacteria was 29.7% (101/340). Escherichia coli (35.6%) and Klebsiella species (32.7%) were predominant ESBL producers. Genotypic analysis revealed blaTEM (49.5%) and blaCTX-M (30.7%) as the most prevalent genes, while blaSHV was less common (7.9%) Conclusion The high prevalence of ESBL–producing bacteria and their resistance to commonly used antibiotics highlight the need for targeted antibiotic therapy, antimicrobial stewardship, and regular molecular surveillance.
- Open Access
- 10 November 2025
- Published by Microbiology Society
- p. 001120.v2
Burden of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae among Cancer Patients in Africa: A Systematic Review and Meta-Analysis
Background : Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) exacerbate infections in cancer patients, in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-PE among cancer patients in Africa from 2010 to 2024. Methods: We searched PubMed, Embase, Web of Science, CINAHL, and Global Health for observational studies reporting ESBL-PE prevalence in cancer patients. Studies published in English from 2010 to 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed by I² statistics and publication bias by funnel plots and Egger’s test. Results: Twelve studies from nine African countries, involving 565 patients (305 events) and 687 samples (338 events), were included. The pooled prevalence was 49.9% (95% CI: 23.1%-76.9%, I² = 91.8%, p < 0.001) at the patient level and 48.1% (95% CI: 31.7%-65.0%, I² = 84.0%, p < 0.001) at the sample level. Escherichia coli and Klebsiella pneumoniae predominated, with high resistance to cephalosporins (median: 89.5%-90%) and fluoroquinolones but preserved carbapenem efficacy. Publication bias was evident, and heterogeneity persisted after sensitivity analysis. Conclusions: The high ESBL-PE prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship, and intentional infection control measures.
- 10 November 2025
- Published by Microbiology Society
- p. 001120.v2
Open AccessBurden of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae among Cancer Patients in Africa: A Systematic Review and Meta-Analysis
Background : Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) exacerbate infections in cancer patients, in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-PE among cancer patients in Africa from 2010 to 2024. Methods: We searched PubMed, Embase, Web of Science, CINAHL, and Global Health for observational studies reporting ESBL-PE prevalence in cancer patients. Studies published in English from 2010 to 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed by I² statistics and publication bias by funnel plots and Egger’s test. Results: Twelve studies from nine African countries, involving 565 patients (305 events) and 687 samples (338 events), were included. The pooled prevalence was 49.9% (95% CI: 23.1%-76.9%, I² = 91.8%, p < 0.001) at the patient level and 48.1% (95% CI: 31.7%-65.0%, I² = 84.0%, p < 0.001) at the sample level. Escherichia coli and Klebsiella pneumoniae predominated, with high resistance to cephalosporins (median: 89.5%-90%) and fluoroquinolones but preserved carbapenem efficacy. Publication bias was evident, and heterogeneity persisted after sensitivity analysis. Conclusions: The high ESBL-PE prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship, and intentional infection control measures.
- Open Access
- 30 September 2025
- Published by Microbiology Society
- p. 001120.v1
Burden of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae among Cancer Patients in Africa: A Systematic Review and Meta-Analysis
Background : Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) exacerbate infections in cancer patients, in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-PE among cancer patients in Africa from 2010 to 2024. Methods: We searched PubMed, Embase, Web of Science, CINAHL, and Global Health for observational studies reporting ESBL-PE prevalence in cancer patients. Studies published in English from 2010 to 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed by I² statistics and publication bias by funnel plots and Egger’s test. Results: Twelve studies from nine African countries, involving 565 patients (305 events) and 687 samples (338 events), were included. The pooled prevalence was 49.9% (95% CI: 23.1%-76.9%, I² = 91.8%, p < 0.001) at the patient level and 48.1% (95% CI: 31.7%-65.0%, I² = 84.0%, p < 0.001) at the sample level. Escherichia coli and Klebsiella pneumoniae predominated, with high resistance to cephalosporins (median: 89.5%-90%) and fluoroquinolones but preserved carbapenem efficacy. Publication bias was evident, and heterogeneity persisted after sensitivity analysis. Conclusions: The high ESBL-PE prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship, and intentional infection control measures.
- 30 September 2025
- Published by Microbiology Society
- p. 001120.v1
Open AccessBurden of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae among Cancer Patients in Africa: A Systematic Review and Meta-Analysis
Background : Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) exacerbate infections in cancer patients, in settings where antimicrobial resistance threatens health outcomes. This study estimated the prevalence of ESBL-PE among cancer patients in Africa from 2010 to 2024. Methods: We searched PubMed, Embase, Web of Science, CINAHL, and Global Health for observational studies reporting ESBL-PE prevalence in cancer patients. Studies published in English from 2010 to 2024 were included. Two reviewers independently screened studies, extracted data using standardized forms, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was calculated using a random-effects model in RStudio v4.4.2, with heterogeneity assessed by I² statistics and publication bias by funnel plots and Egger’s test. Results: Twelve studies from nine African countries, involving 565 patients (305 events) and 687 samples (338 events), were included. The pooled prevalence was 49.9% (95% CI: 23.1%-76.9%, I² = 91.8%, p < 0.001) at the patient level and 48.1% (95% CI: 31.7%-65.0%, I² = 84.0%, p < 0.001) at the sample level. Escherichia coli and Klebsiella pneumoniae predominated, with high resistance to cephalosporins (median: 89.5%-90%) and fluoroquinolones but preserved carbapenem efficacy. Publication bias was evident, and heterogeneity persisted after sensitivity analysis. Conclusions: The high ESBL-PE prevalence in African cancer patients signals a critical public health issue, necessitating enhanced surveillance, antimicrobial stewardship, and intentional infection control measures.
- Open Access
- 8 September 2025
- Published by Microbiology Society
- p. 001045.v3
Prevalence and Molecular Characterization of Extended Spectrum Beta Lactamase Bacteria Causing Urinary Tract Infections in Pregnant Mothers at Itojo Hospital, South Western Uganda
Background Extended-spectrum β-lactamase (ESBL) producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents that complicate available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary internationally to inform the effective treatment guidelines. Objective To determine the prevalence and molecular characterization of ESBL bacteria causing Urinary Tract Infections (UTIs) in women who are pregnant at the Itojo Hospital, Ntungamo District. Methods We conducted cross-sectional study where we collected and analyzed 340 urine samples. We did antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Isolates were screened for ESBL production and confirmed using the combination disk test (CDT). Genotypic characterization was confirmed using multiplex PCR to detect blaTEM, blaCTX-M and blaSHV genes. Results The prevalence of ESBL – producing bacteria was 29.7% (101/340). Escherichia coli (35.6%) and Klebsiella species (32.7%) were predominant ESBL producers. Genotypic analysis revealed blaTEM (49.5%) and blaCTX-M (30.7%) as the most prevalent genes, while blaSHV was less common (7.9%) Conclusion The high prevalence of ESBL–producing bacteria and their resistance to commonly used antibiotics highlight the need for targeted antibiotic therapy, antimicrobial stewardship, and regular molecular surveillance.
- 8 September 2025
- Published by Microbiology Society
- p. 001045.v3
Open AccessPrevalence and Molecular Characterization of Extended Spectrum Beta Lactamase Bacteria Causing Urinary Tract Infections in Pregnant Mothers at Itojo Hospital, South Western Uganda
Background Extended-spectrum β-lactamase (ESBL) producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents that complicate available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary internationally to inform the effective treatment guidelines. Objective To determine the prevalence and molecular characterization of ESBL bacteria causing Urinary Tract Infections (UTIs) in women who are pregnant at the Itojo Hospital, Ntungamo District. Methods We conducted cross-sectional study where we collected and analyzed 340 urine samples. We did antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Isolates were screened for ESBL production and confirmed using the combination disk test (CDT). Genotypic characterization was confirmed using multiplex PCR to detect blaTEM, blaCTX-M and blaSHV genes. Results The prevalence of ESBL – producing bacteria was 29.7% (101/340). Escherichia coli (35.6%) and Klebsiella species (32.7%) were predominant ESBL producers. Genotypic analysis revealed blaTEM (49.5%) and blaCTX-M (30.7%) as the most prevalent genes, while blaSHV was less common (7.9%) Conclusion The high prevalence of ESBL–producing bacteria and their resistance to commonly used antibiotics highlight the need for targeted antibiotic therapy, antimicrobial stewardship, and regular molecular surveillance.
- Open Access
- 25 July 2025
- Published by Microbiology Society
- p. 001089.v1
Molecular detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones at Mbarara City Health Centre IV, Southwestern Uganda
Introduction: Helicobacter pylori infection is classified as a human carcinogen that is linked to gastric cancer; the third most common cause of cancer death worldwide. Unfortunately, there is an emerging antimicrobial resistance to commonly used antibiotics in the treatment of H. pylori thus knowing the local prevalence rate of resistance using a molecular test is important to describe evidence-based interventions. Objective(s): To determine the prevalence of resistance of H. pylori to clarithromycin and fluoroquinolones using a molecular test at Mbarara City Health Centre IV, Southwestern Uganda. Method s: We conducted a descriptive cross-sectional study from January 2020 to April 2021where informed consents were obtained from patients who presented with gastrointestinal symptoms. An interview-guided questionnaire was used to collect both demographic and clinical data. Each participant was provided with a sterile stool container and given instructions to collect four scoopfuls of stools. The stool specimen was placed in a cool box and transported to the laboratory within 30 minutes of sample collection for H. pylori antigen analysis and those that were positive for H. pylori were stored in a fridge at a temperature of -20ᵒc for a week, then transported to MBN clinical laboratories for DNA Extraction from stool using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden Germany) to identify the presence of H. pylori and point mutations in the genes responsible for resistance to fluoroquinolone and clarithromycin through multiplex amplification, and reverse hybridization. Associations were determined using Chi square with Fisher’s exact test and statistical significance was set at P < 0.05. Stata (version 18) was used for statistical analysis. Results: The prevalence of H. pylori among participants who presented with Gastrointestinal Symptoms (GIS) was 27%. Sanitation, smoking, source of drinking water, and bloody stool were found to be associated with H. pylori infection. The proportion of H. pylori resistant to clarithromycin (CLA) was 40% and that to fluoroquinolones (FLQ) was 70%. All H. pylori resistant samples to CLA showed a mutation in the 23srRNA gene and for all that were resistant to FLQ, a mutation was detected in the gyrase A gene. Conclusion: There was a high prevalence of H. pylori infection among participants who presented with GIS and these were associated with poor sanitation, smoking, source of drinking water, and bloody stool. H. pylori was highly resistant to FLQ followed by CLA hence limiting the treatment options. This calls for precautions while using these drugs in treatment of H. pylori infection Key words: Helicobacter pylori, resistance to clarithromycin and fluoroquinolones
- 25 July 2025
- Published by Microbiology Society
- p. 001089.v1
Open AccessMolecular detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones at Mbarara City Health Centre IV, Southwestern Uganda
Introduction: Helicobacter pylori infection is classified as a human carcinogen that is linked to gastric cancer; the third most common cause of cancer death worldwide. Unfortunately, there is an emerging antimicrobial resistance to commonly used antibiotics in the treatment of H. pylori thus knowing the local prevalence rate of resistance using a molecular test is important to describe evidence-based interventions. Objective(s): To determine the prevalence of resistance of H. pylori to clarithromycin and fluoroquinolones using a molecular test at Mbarara City Health Centre IV, Southwestern Uganda. Method s: We conducted a descriptive cross-sectional study from January 2020 to April 2021where informed consents were obtained from patients who presented with gastrointestinal symptoms. An interview-guided questionnaire was used to collect both demographic and clinical data. Each participant was provided with a sterile stool container and given instructions to collect four scoopfuls of stools. The stool specimen was placed in a cool box and transported to the laboratory within 30 minutes of sample collection for H. pylori antigen analysis and those that were positive for H. pylori were stored in a fridge at a temperature of -20ᵒc for a week, then transported to MBN clinical laboratories for DNA Extraction from stool using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden Germany) to identify the presence of H. pylori and point mutations in the genes responsible for resistance to fluoroquinolone and clarithromycin through multiplex amplification, and reverse hybridization. Associations were determined using Chi square with Fisher’s exact test and statistical significance was set at P < 0.05. Stata (version 18) was used for statistical analysis. Results: The prevalence of H. pylori among participants who presented with Gastrointestinal Symptoms (GIS) was 27%. Sanitation, smoking, source of drinking water, and bloody stool were found to be associated with H. pylori infection. The proportion of H. pylori resistant to clarithromycin (CLA) was 40% and that to fluoroquinolones (FLQ) was 70%. All H. pylori resistant samples to CLA showed a mutation in the 23srRNA gene and for all that were resistant to FLQ, a mutation was detected in the gyrase A gene. Conclusion: There was a high prevalence of H. pylori infection among participants who presented with GIS and these were associated with poor sanitation, smoking, source of drinking water, and bloody stool. H. pylori was highly resistant to FLQ followed by CLA hence limiting the treatment options. This calls for precautions while using these drugs in treatment of H. pylori infection Key words: Helicobacter pylori, resistance to clarithromycin and fluoroquinolones
- Open Access
- 7 July 2025
- Published by Microbiology Society
- p. 001045.v2
Prevalence and Molecular Characterization of Extended Spectrum Beta Lactamase Bacteria Causing Urinary Tract Infections in Pregnant Mothers at Itojo Hospital, South Western Uganda
Background Extended-spectrum β-lactamase (ESBL) producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents that complicate available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary internationally to inform the effective treatment guidelines. Objective To determine the prevalence and molecular characterization of ESBL bacteria causing Urinary Tract Infections (UTIs) in women who are pregnant at the Itojo Hospital, Ntungamo District. Methods We conducted cross-sectional study where we collected and analyzed 340 urine samples. We did antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Isolates were screened for ESBL production and confirmed using the combination disk test (CDT). Genotypic characterization was confirmed using multiplex PCR to detect blaTEM, blaCTX-M and blaSHV genes. Results The prevalence of ESBL – producing bacteria was 29.7% (101/340). Escherichia coli (35.6%) and Klebsiella species (32.7%) were predominant ESBL producers. Genotypic analysis revealed blaTEM (49.5%) and blaCTX-M (30.7%) as the most prevalent genes, while blaSHV was less common (7.9%) Conclusion The high prevalence of ESBL–producing bacteria and their resistance to commonly used antibiotics highlight the need for targeted antibiotic therapy, antimicrobial stewardship, and regular molecular surveillance.
- 7 July 2025
- Published by Microbiology Society
- p. 001045.v2
Open AccessPrevalence and Molecular Characterization of Extended Spectrum Beta Lactamase Bacteria Causing Urinary Tract Infections in Pregnant Mothers at Itojo Hospital, South Western Uganda
Background Extended-spectrum β-lactamase (ESBL) producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents that complicate available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary internationally to inform the effective treatment guidelines. Objective To determine the prevalence and molecular characterization of ESBL bacteria causing Urinary Tract Infections (UTIs) in women who are pregnant at the Itojo Hospital, Ntungamo District. Methods We conducted cross-sectional study where we collected and analyzed 340 urine samples. We did antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Isolates were screened for ESBL production and confirmed using the combination disk test (CDT). Genotypic characterization was confirmed using multiplex PCR to detect blaTEM, blaCTX-M and blaSHV genes. Results The prevalence of ESBL – producing bacteria was 29.7% (101/340). Escherichia coli (35.6%) and Klebsiella species (32.7%) were predominant ESBL producers. Genotypic analysis revealed blaTEM (49.5%) and blaCTX-M (30.7%) as the most prevalent genes, while blaSHV was less common (7.9%) Conclusion The high prevalence of ESBL–producing bacteria and their resistance to commonly used antibiotics highlight the need for targeted antibiotic therapy, antimicrobial stewardship, and regular molecular surveillance.